Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices (original) (raw)

Blood, 2017

Abstract

BACKGROUND Acute Lymphoblastic Leukemia (ALL) in adults is a rare malignancy associated with high rates of relapse and poor outcomes. Despite the availability of multi-agent chemotherapies and the recently-approved novel targeted therapy blinatumomab (BLINA), most adults with relapsed or refractory (R/R) ALL are unlikely to achieve remission, undergo hematopoietic cell transplant (HCT), and experience long-term survival. The objective of this study was to determine current real-world standard of care, patient characteristics, healthcare resource utilization, and outcomes for adult R/R ALL after first relapse. Here we report patient characteristics, treatment patterns, and outcomes for this population. METHODS We conducted a retrospective study using Symphony Health Solutions9 Integrated Dataverse, a longitudinal transactional database that includes prescription, medical and hospital claims across > 4,900 US payers. Eligible patients were >15 yr, and had at least 1 ICD-9 or ICD...

Michael Benigno hasn't uploaded this paper.

Let Michael know you want this paper to be uploaded.

Ask for this paper to be uploaded.